CD38 and myelodysplastic syndrome: The continued relevance of the CD34/CD38 marker combination is exemplified in two recently published studies regarding the prognostic significance of a high CD34+/CD38- stem cell burden in patients with myelodysplastic syndromes and acute myeloid leukemia [35,36].